TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/10/2025
Voltar para busca
Dado oficial do USPTO
ASTARTZ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
22/10/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 40, 42, 45
Data de depósito
25/02/2022
Data de registro
22/08/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/08/2023
Última transação
22/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
Tokyo 136-0075, JP
Examinador
EISNACH,MICHAEL PATRICK
Unidade examinadora
L40
Localização atual
TMEG LAW OFFICE 104
Descrição da marca
The mark consists of the Greek letter "alpha" before the term "STARTZ" appearing as one word in stylized format.
Titulares e representantes
Titulares
NIHON MEDI-PHYSICS CO., LTD.
Representantes
Marina Dostal GE Precision Healthcare LLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Industrial chemicals; chemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of radiopharmaceuticals; radioactive elements for scientific purposes; isotopes for industrial purposes; peptide substrates for scientific purposes; peptide for use in the manufacture of pharmaceuticals; chelating agents for use in the manufacture of pharmaceuticals; polypeptides for scientific purposes; antibodies for scientific purposesother than for medical or veterinary use; chelate compound; organic chelating agents; metal chelating agents
Classe 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the diagnosis of cancer; chemical reagents for medical purposes; medical diagnostic reagents; radioactive substances for medical purposes; isotopes for medical purposes; radioisotope markers for therapeutic or diagnostic use; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; synthetic peptides for pharmaceutical purposes for the treatment of cancer; synthetic peptides for pharmaceutical purposes for the diagnosis of cancer; pharmaceuticals consisting of antibodies for the treatment of cancer; pharmaceuticals consisting of antibodies for the diagnosis of cancer; pharmaceuticals consisting of antibody fragments for the treatment of cancer; pharmaceuticals consisting of antibody fragments for the diagnosis of cancer; pharmaceuticals consisting of antibody derivatives for the treatment of cancer; pharmaceuticals consisting of antibody derivatives for the diagnosis of cancer; antibodies for medical purposes
Classe 40
Custom manufacture of pharmaceuticals; custom manufacture of investigational new drug; custom manufacture of radiopharmaceuticals; custom synthesis of labeled compound; custom manufacture of peptides; custom manufacture of antibodies; custom manufacture of proteins; custom protein modification; custom antibody modification; custom extraction of pharmaceuticals and veterinary preparations; custom synthesis and refining of pharmaceuticals and veterinary preparations; custom peptide synthesis services; custom synthesis and refining of pharmaceuticals consisting of antibodies; custom manufacture of pharmaceuticals consisting of antibodies; custom synthesis and refining of pharmaceuticals consisting of antibody fragments; custom manufacture of pharmaceuticals consisting of antibody fragments; custom synthesis and refining of pharmaceuticals consisting of antibody derivatives; custom manufacture of pharmaceuticals consisting of antibody derivatives; custom radioactive labeling of antibodies; custom radioactive labeling of antibody fragments; custom radioactive labeling of antibody derivatives; custom radioactive labeling of peptides
Classe 42
Research and development of medicines; testinginspection or research services in the fields of pharmaceuticals; advisoryconsultancy and providing information relating to testinginspection or research services in the fields of pharmaceuticals; development of pharmaceuticals; advisoryconsultancy and providing information relating to development of pharmaceuticals; conducting clinical trials for pharmaceuticals for others; advisoryconsultancy and providing information relating to clinical trials for pharmaceuticals; research and development of radiopharmaceuticals; development of radiopharmaceuticals; advisoryconsultancy and providing information relating to development of radiopharmaceuticals; research and development services relating to peptides; research and development services in the field of antibodies; research and development services relating to peptide labeling by radioactive substances; research and development services relating to antibody labeling by radioactive substances
Classe 45
Granting of licenses to others for the use of intellectual property; legal servicesexploitation of industrial property rights
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/10/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/10/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/10/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/10/2025
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
18/06/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
10/05/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/05/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/12/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
27/11/2023
FIMP
FINAL DISPOSITION PROCESSED
27/11/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/11/2023
ES7R
TEAS SECTION 7 REQUEST RECEIVED
28/08/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
22/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
22/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/06/2023
CHPB
POST PUBLICATION AMENDMENT - ENTERED
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/06/2023
PUBO
PUBLISHED FOR OPPOSITION
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/05/2023
APET
ASSIGNED TO PETITION STAFF
15/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/05/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/05/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/05/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/05/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
26/04/2023
PBMR
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
25/04/2023
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
22/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/04/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/04/2023
RFNT
REFUSAL PROCESSED BY IB
06/03/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/02/2023
RFRR
REFUSAL PROCESSED BY MPU
15/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/12/2022
CNRT
NON-FINAL ACTION WRITTEN
19/12/2022
DOCK
ASSIGNED TO EXAMINER
09/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
28/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/06/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
22/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/06/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ASTARTZ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.